KEYNOTE-667: PHASE 2 STUDY OF PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE TO FRONTLINE CHEMOTHERAPY

被引：0
|
作者：
Vinti, Luciana [1 ]
Daw, Stephen [2 ]
Alvarez, Constantino Sabado [3 ]
Fagioli, Franca [4 ]
Beishuizen, Auke [5 ]
Michel, Gerard [6 ]
Moleti, Maria Luisa [7 ]
Cepelova, Michaela [8 ]
Thorwarth, Anne [9 ]
Rigaud, Charlotte [10 ]
De Sabando, Diego Plaza Lopez [11 ]
Parker, Judith Landman [12 ]
Zhu, Ying [13 ]
Pillai, Pallavi [13 ]
Nahar, Akash [13 ]
Mauz-Koerholz, Christine [14 ,15 ]
机构：
[1] IRCCS Osped Pediatrico Bambino Gesu, Pediat Hematol & Oncol, Rome, Italy
[2] Univ Coll London Hosp NHS Fdn Trust, Pediat & Hematol Oncol, London, England
[3] Hosp Univ Vall Hebron, Pediat Oncol, Barcelona, Spain
[4] Osped Infantile Regina Margherita, Pathol & Child Care, Turin, Italy
[5] Princess Maxima Centrum, Hematol Malignancies, Utrecht, Netherlands
[6] CHU Marseille, Hop Timone Enfants, Pediat & Pediat Hematol, Marseille, France
[7] Univ Roma La Sapienza, Pediat Hematol & Oncol, Rome, Italy
[8] Fak Nemocnice Motole, Pediat Hematol & Oncol, Prague, Czech Republic
[9] Charite Univ Med Berlin, Campus Virchow Klinikum, Pediat Oncol & Hematol, Berlin, Germany
[10] Gustave Roussy Canc Campus, Pediat Hematol & Oncol, Villejuif, France
[11] Hosp Univ La Paz, Pediat Hematol & Oncol, Madrid, Spain
[12] Hop Enfants Armand Trousseau, Pediat, Paris, France
[13] Merck Co Inc, Med Oncol, Kenilworth, NJ USA
[14] Justus Liebig Univ Giessen, Giessen, Germany
[15] Martin Luther Univ Halle Wittenberg, Fac Med, Pediat Hematol & Oncol, Halle, Germany
来源：
PEDIATRIC BLOOD & CANCER | 2022年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O046
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Risk Adapted Therapy Utilizing Upfront Brentuximab Vedotin (Bv) and Rituximab (R) with Reduced Toxicity Chemotherapy in the Treatment OF Children, Adolescents and Young Adults (CAYA) with Newly Diagnosed Hodgkin Lymphoma (HL)
    Hochberg, Jessica
    Klejmont, Liana
    Harrison, Lauren
    Flower, Allyson
    Shi, Qiuhu
    Basso, Jaclyn
    Cairo, Mitchell
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S3 - S3
  • [32] Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin's lymphoma: a phase II, non-randomized controlled trial
    Hochberg, Jessica
    Basso, Jaclyn
    Shi, Qiuhu
    Klejmont, Liana
    Flower, Allyson
    Bortfeld, Kristina
    Harrison, Lauren
    van de Ven, Carmella
    Moorthy, Chitti
    Islam, Humayun
    Gerard, Perry
    Voss, Stephan
    Cairo, Mitchell S.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (05)
  • [33] A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study
    Horton, Terzah M.
    Drachtman, Richard A.
    Chen, Lu
    Cole, Peter D.
    McCarten, Kathleen
    Voss, Stephan
    Guillerman, Robert P.
    Buxton, Allen
    Howard, Scott C.
    Hogan, Shirley M.
    Sheehan, Andrea M.
    Lopez-Terrada, Dolores
    Mrazek, Matthew D.
    Agrawal, Neeraj
    Wu, Meng-Fen
    Liu, Hao
    De Alarcon, Pedro A.
    Trippet, Tanya M.
    Schwartz, Cindy L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (01) : 118 - 122
  • [34] KEYNOTE B68: Open-label phase 2 study of the efficacy and safety of pembrolizumab administered every six weeks in patients with relapsed or refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma.
    Armand, Philippe
    Pathiraja, Kumudu
    Chakraborty, Samhita
    Marinello, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] Interim PET-Adapted De-Escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Safety and Efficacy Study
    Lee, Hun Ju
    Ravizzini, Gregory
    Aboismail, Eslam
    Wixom, Jenna
    Henderson, Jared
    Fayad, Luis E.
    Ahmed, Sairah
    Nair, Ranjit
    Westin, Jason R.
    Lyer, Swaminathan P.
    Nze, Chijioke
    Al Zaki, Ajlan
    Vega, Francisco
    Wang, Michael
    Flowers, Christopher R.
    Malpica, Luis
    BLOOD, 2024, 144 : 16743 - 16744
  • [36] Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate-Risk Hodgkin Lymphoma: A Report From the Children's Oncology Group Study AHOD0031
    Friedman, Debra L.
    Chen, Lu
    Wolden, Suzanne
    Buxton, Allen
    McCarten, Kathleen
    FitzGerald, Thomas J.
    Kessel, Sandra
    De Alarcon, Pedro A.
    Chen, Allen R.
    Kobrinsky, Nathan
    Ehrlich, Peter
    Hutchison, Robert E.
    Constine, Louis S.
    Schwartz, Cindy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (32) : 3651 - 3658
  • [37] A PHASE 2 STUDY OF BORTEZOMIB (VELCADE) IN COMBINATION WITH IFOSFAMIDE AND VINORELBINE IN PEDIATRIC PATIENTS AND YOUNG ADULTS WITH REFRACTORY/RECURRENT HODGKIN LYMPHOMA: A CHILDREN'S ONCOLOGY GROUP (COG) STUDY
    Horton, T. M.
    Drachtman, R. A.
    Chen, L.
    Trippett, T. M.
    Alarcon, P.
    Chen, A. R.
    Guillerman, R. P.
    Sheehan, A.
    Lopez-Terrada, L.
    Schwartz, C. L.
    HAEMATOLOGICA, 2010, 95 : S52 - S52
  • [38] PHASE III STUDY OF RESPONSE ADAPTED THERAPY FOR THE TREATMENT OF CHILDREN WITH NEWLY DIAGNOSED VERY HIGH RISK HODGKIN LYMPHOMA (STAGES IIIB/IVB) (AHOD0831): A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
    Kelly, K.
    Cole, P. D.
    Chen, L.
    Roberts, K. B.
    Hodgson, D. C.
    McCarten, K.
    Cho, S. Y.
    Schwartz, C. L.
    HAEMATOLOGICA, 2016, 101 : 34 - 34
  • [39] Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed Very High Risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): A Report from the Children's Oncology Group
    Kelly, Kara M.
    Cole, Peter D.
    Chen, Lu
    Roberts, Kenneth B.
    Hodgson, David C.
    McCarten, Kathleen
    Cho, Steve Y.
    Schwartz, Cindy
    BLOOD, 2015, 126 (23)
  • [40] AHOD2131: A Randomized Phase 3 Response-Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
    Henderson, Tara O.
    Hu, Boyu
    Keller, Frank
    Pei, Qinglin
    Wu, Yue
    Hoppe, Bradford
    Milgrom, Sarah
    Yao, Song
    Khan, Niloufer
    Roth, Lisa Giulino
    Mailhot, Raymond
    Cho, Steve
    Parsons, Susan K.
    Kahn, Justine M.
    Duvall, Adam S.
    Hinds, Pamela S.
    LaCasce, Ann
    Grover, Natalie S.
    Allen, Pamela B.
    Evens, Andrew M.
    Schoder, Heiko
    Castellino, Sharon M.
    Kelly, Kara M.
    BLOOD, 2023, 142
12345